Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide.
Objectives: The Scleroderma Lung Study showed the efficacy of cyclophosphamide in modestly improving the forced vital capacity (FVC) compared with placebo over 1 year. Using changes in texture-based scores that quantify lung fibrosis as the percentage involvement of reticulation patterns, the effect...
| Publicado en: | European Radiology Vol. 21; no. 12; pp. 2455 - 2466 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | clinical trial research Journal Article |
| Publicado: |
Springer Nature
Dec2011
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104601642&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104601642 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09387994 NPH jtl: European Radiology issn: 09387994 maglogo: N pubinfo: dt: Dec2011 vid: 21 iid: 12 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 104601642 67224574 NLM21927793 2011375647 10.1007/s00330-011-2223-2 NLM21927793 104601642 ppf: 2455 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. aug: au: Kim HJ Brown MS Elashoff R Li G Gjertson DW Lynch DA Strollo DC Kleerup E Chong D Shah SK Ahmad S Abtin F Tashkin DP Goldin JG Kim, Hyun J Brown, Matthew S Elashoff, Robert Li, Gang Gjertson, David W Lynch, David A affil: Center for Computer Vision and Imaging Biomarker, Department of Radiological Sciences, David Geffen School of Medicine, UCLA, 924 Westwood Blvd., Suite 650, Los Angeles, CA 90024-2926, USA sug: subj: Cyclophosphamide Therapeutic Use Lung Diseases, Interstitial Pathology Lung Diseases, Interstitial Radiography Tomography, X-Ray Computed Methods Administration, Oral Adult Aged Disease Progression Female Fibrosis Drug Therapy Human Lung Diseases, Interstitial Drug Therapy Male Middle Age Prospective Studies Reproducibility of Results Treatment Outcomes Vital Capacity Drug Effects Clinical Trials Adult: 19-44 years Aged: 65+ years Middle Aged: 45-64 years Female Male ab: Objectives: The Scleroderma Lung Study showed the efficacy of cyclophosphamide in modestly improving the forced vital capacity (FVC) compared with placebo over 1 year. Using changes in texture-based scores that quantify lung fibrosis as the percentage involvement of reticulation patterns, the effectiveness of cyclophosphamide was re-assessed by examining its impact on quantitative lung fibrosis (QLF).Methods: Axial HRCT images were acquired (1-mm slice thickness, 10-mm increments) in the prone position at inspiration. A validated model for quantifying interstitial disease patterns was applied to images from 83 subjects at baseline and 12 months. Scores were calculated for six zones (upper, mid, lower of the right/left lung) and the whole lung. Average changes were compared. Correlations were performed between QLF and physiological and clinical scores.Results: From the most severe zones identified at baseline, QLF scores decreased by 2.6% in the cyclophosphamide group, whereas they increased by 9.1% in the placebo group, leading to ~12% difference (p = 0.0027). Between-treatment difference in whole lung QLF was ~5% (p = 0.0190). Significant associations were observed between changes in QLF and FVC (r = -0.33), dyspnea score (r = -0.29), and consensus visual score (p = 0.0001).Conclusions: QLF scores provide an objective quantitative tool for assessing treatment efficacy in scleroderma-related interstitial lung disease. pubtype: Academic Journal doctype: clinical trial research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|